The latest whisky deals on Amazon offer the chance to explore some exotic flavour profiles for bargain prices - and we’ve selected three of the best from Jura, ...
UNIVERSITY research incubator Fusion IP said today its portfolio company Diurnal had overome a European regulatory hurdle after receiving approval for a paediatric version of hydrocortisone.
FUSION IP has made its first major “exit”, selling simulation firm Simcyp to a US drug firm for about £20m ($32m) to net hefty gains.
Did you know with a Digital subscription to Yorkshire Post, you can get access to all of our premium content, as well as benefiting from fewer ads, loyalty rewards and much more.
